Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)

Approved for use through 07/31/2012. OMB 0651-0031

mation Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10084380	
	Filing Date		2002-02-28	
INFORMATION DISCLOSURE	First Named Inventor	Daniel G. Chain		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1649	
THOUSE SUBMISSION GREET OF OTTE 1.00,	Examiner Name	Grego	ory S. Emch	
	Attorney Docket Number		27580-0003001	

				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5589154		1996-12-31	Anderson			
If you wish	n to ac	 dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.	Add	
			U.S.P	ATENT APPL	CATION PUB	LICATIONS	Remove	
Examiner Initial*	Cite I	No Publication Number	Kind Code <sup>1</sup>	Publication Date			Pages,Columns,Lines where Relevant Passages or Relev Figures Appear	
If you wisl	1 n to ac	dd additional U.S. Pub	lished Ap	plication citatic	n information	please click the Ad	d button. Add	
				FOREIGN PA			Remove	7
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Publication Date	Name of Patente Applicant of cited Document	Where Relevant	T5
	1	WO 94/25585	wo		1994-11-10	LONBERG, Nils		
	2	EP1200476B1	EP		2009-05-27	ROCK et al.		
If you wisl	n to ac	 ld additional Foreign F		cument citation	· ·		I button Add Remove	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

	_	
Application Number		10084380
Filing Date		2002-02-28
First Named Inventor Danie		l G. Chain
Art Unit		1649
Examiner Name Grego		ory S. Emch
Attorney Docket Number		27580-0003001

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	COTMAN, C.W., The β-amyloid peptide, peptide self-assembly, and the emergence of biological activities: a new principle in peptide function and the induction of neuropathology, Annals NY Acad Sci, Vol. 814, pages 1-816, 1997	
	2	BEHL, C., Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease, Cell Tissue Res, Vol. 290, pages 471-480, 1997	
	3	Page downloaded 27 October 2011 from website "Alzheimer Research Forum" at www.alzforum.org/res/com/ant/default.asp after searching for "3D6 AND Johnson-Wood"	
	4	Provisional and non-binding opinion of the Opposition Division dated November 12, 2010, issued by the European Patent Office in connection with opposition filed against European Patent No. 0 994 728, which issued from counterpart application EP 98918035.1, 5 pages	
	5	Minutes of Oral Proceedings before the Opposition Division held on July 1, 2011, in connection with opposition filed against European Patent No. 0 994 728, which issued from counterpart application EP 98918035.1; dated July 26, 2011, 4 pages	
	6	Decision revoking the European Patent, dated October 7, 2011, issued by the European Patent Office in connection with opposition filed against European Patent No. 0 994 728, which issued from counterpart application EP 98918035.1, 26 pages	
	7	ITO et al., Cerebral clearance of human amyloid-β peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes, J Neurochemistry, Vol. 103, pages 2482-2490, 2007	
	8	Declaration of Dr. K. Rock, dated 28 April 2011, filed in connection with opposition filed against European Patent No. 0 994 728, which issued from counterpart application EP 98918035.1, 8 pages	
	9	The American Heritage Dictionary, 3rd Edition, page 1953	
	10	Immunobiology, 6th Edition, page 688	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10084380
Filing Date		2002-02-28
First Named Inventor Danie		l G. Chain
Art Unit		1649
Examiner Name Grego		ory S. Emch
Attorney Docket Number		27580-0003001

	11	Funda	amental Immunology, 6th Edition, pages 170-171				
	12	VAN	N REGENMORTEL, M., J. Immunological Methods, Vol. 216, pages 37-48, 1998				
If you wis	sh to a	dd add	litional non-patent literature document citation information pleas	se click the Add b	outton Add		
			EXAMINER SIGNATURE				
Examine	r Signa	ature	Da	te Considered			
			reference considered, whether or not citation is in conformance mance and not considered. Include copy of this form with next		_		
Standard S  4 Kind of do	ST.3). <sup>3</sup> ocument	For Japa by the a	O Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>2</sup> Enter office that anese patent documents, the indication of the year of the reign of the Emperor appropriate symbols as indicated on the document under WIPO Standard ST.1 in is attached.	must precede the ser	ial number of the patent doc	ument.	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10084380	
Filing Date		2002-02-28	
First Named Inventor Danie		el G. Chain	
Art Unit		1649	
Examiner Name Grego		bry S. Emch	
Attorney Docket Number		27580-0003001	

Ple	ase see 37 CFR	R 1.97 and 1.98 to make the appropriate se	lection(s):				
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).						
OF	2						
	foreign patent after making ra any individual	of information contained in the information office in a counterpart foreign application easonable inquiry, no item of information of designated in 37 CFR 1.56(c) more that e 37 CFR 1.97(e)(2).	n, and, to the knowledge of t contained in the information o	he person signing the certification lisclosure statement was known to			
	See attached	certification statement.					
	The fee set for	rth in 37 CFR 1.17 (p) has been submitted	herewith.				
×	A certification	statement is not submitted herewith.					
	signature of the n of the signatur	applicant or representative is required in a	SNATURE ccordance with CFR 1.33, 10.	18. Please see CFR 1.4(d) for the			
Sig	nature	/Mitchell Bernstein, Reg. No. 46,550/	Date (YYYY-MM-DD)	2011-11-01			
Nar	me/Print	Mitchell Bernstein	Registration Number	46550			
pub 1.14 app	olic which is to fil 4. This collection dication form to	formation is required by 37 CFR 1.97 and le (and by the USPTO to process) an applion is estimated to take 1 hour to complete, ithe USPTO. Time will vary depending upoet this form and/or suggestions for reducing	cation. Confidentiality is gove including gathering, preparing on the individual case. Any co	erned by 35 U.S.C. 122 and 37 CFR and submitting the completed omments on the amount of time you			

Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria**,

**CERTIFICATION STATEMENT** 

VA 22313-1450.

## **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.